The shorter multidrug-resistant tuberculosis treatment regimen in Singapore: are patients from South-East Asia eligible?

Eur Respir J. 2017 Aug 10;50(2):1700753. doi: 10.1183/13993003.00753-2017. Print 2017 Aug.

Authors

Cynthia B E Chee^{1

2}, Kyi-Win KhinMar², Li-H Sng³, Roland Jureen⁴, Jeffery Cutter⁵, Vernon J M Lee⁵, Yee-Tang Wang^{6

2}

Affiliations

¹ Respiratory Medicine, Tan Tock Seng Hospital, Singapore, Singapore cynthia_chee@ttsh.com.sg.
² Tuberculosis Control Unit, Tan Tock Seng Hospital, Singapore, Singapore.
³ Dept of Pathology, Singapore General Hospital, Singapore, Singapore.
⁴ National University Health System (NUHS), Singapore, Singapore.
⁵ Communicable Diseases Division, Ministry of Health, Singapore, Singapore.
⁶ Respiratory Medicine, Tan Tock Seng Hospital, Singapore, Singapore.

PMID: 28798092
DOI: 10.1183/13993003.00753-2017

No abstract available

Publication types

Letter

MeSH terms

Antitubercular Agents / administration & dosage*
Asia, Southeastern
Drug Administration Schedule
Humans
Mycobacterium tuberculosis / isolation & purification
Singapore
Treatment Outcome
Tuberculosis, Multidrug-Resistant / drug therapy*

Substances

Antitubercular Agents